Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology

29.08.2005


Chicken-produced antibodies demonstrate enhanced cell killing compared to conventionally produced anti-cancer antibodies

Origen Therapeutics today announced the first published scientific report of fully functional, human sequence monoclonal antibodies (mAbs) produced in chickens. The antibodies were expressed solely in the chicken oviduct and deposited into egg white in concentrations of 1-3 milligrams per egg. Moreover, antibodies produced in this manner demonstrated 10-100 fold greater cell-killing ability (ADCC) compared to therapeutic antibodies produced by conventional cell culture methods.

The new report was published in the September issue of Nature Biotechnology by researchers from Origen Therapeutics and their collaborators at Medarex, Texas A&M University and the University of California, Los Angeles. A research brief commenting on the potential impact of this development for the production of human therapeutic proteins was also published in the September issue of Nature Medicine.



"This work demonstrates the potential for producing therapeutic proteins with enhanced properties in the eggs of chickens as an alternative to established mammalian cell culture systems," said Robert J. Etches, Ph.D., D. Sc., Origen Therapeutics vice president, research. "Antibodies produced by this method had very similar physical and biological characteristics to those produced in CHO cells, including nearly identical binding curves, similar affinities, and an equal ability to be internalized by antigen on prostate cancer cells. At the same time, chicken-produced antibodies lacked the sugar residue, fucose, which greatly increases their cell-killing activity compared to CHO-produced antibodies."

To create the antibody-producing chickens, the researchers first inserted into chicken embryonic stem cells the genes encoding the antibody and the regulatory sequences restricting its deposition to egg white. The stem cells were then introduced into chick embryos. At this stage of development, the embryonic stem cells can make significant contributions to the developing chicken. Resulting chimeras with large contributions from the stem cells lay eggs containing milligram amounts of antibody, which is then separated from the egg white proteins generating the purified product.

"This work represents a considerable advance over past efforts to develop avian transgenes, which were limited to the insertion of only small pieces of DNA," commented Dr. Etches. "The technology described here is a general method for inserting DNA encoding proteins of essentially any size and complexity while achieving high levels of protein expression. Moreover, it is the only technology to date that restricts deposition of the therapeutic protein to egg white."

"Monoclonal antibodies have demonstrated great success as human therapeutics, with over 25 approved for human therapeutic use and an increasing number of these proteins in clinical development," continued Dr. Etches. "We expect the demand for more potent anti-cancer monoclonal antibodies and for lower production costs to increase at a rate that will tax existing cell culture production systems. The introduction of this new chicken-based production technology will be of considerable interest to an industry coping with the commercial supply of an ever increasing number of therapeutic antibodies."

"We believe the chicken system is an attractive one for therapeutic protein production compared to either plant systems or to other transgenic animal systems," said Robert Kay, Ph.D., Origen Therapeutics president and chief executive officer. "The fact that the chicken-produced anti-cancer antibodies show dramatically enhanced cell killing activity elevates the chicken system considerably relative to other non-traditional production technologies and some traditional cell culture methods as well."

"Furthermore," Dr. Kay continued, "unlike other transgenic animal systems, the time from antibody identification to production in eggs can be as short as 8 months versus 18 months to 3 years for goats or cattle. The egg is sterile and stable, providing a good starting material for isolation and purification of the protein of interest. Moreover, conditions for good manufacturing practices have been long-established for vaccine production in chicken eggs."

"This work really exemplifies the spirit of our Small Business Innovation Research grant program," said Matthew E. Portnoy, Ph.D., program director at the National Institute of General Medical Sciences at the National Institutes of Health. "This new technology has the potential to drive down drug manufacturing costs, which could make medicines and health insurance plans less expensive for all of us."

Ellen M. Martin | EurekAlert!
Further information:
http://www.origentherapeutics.com
http://www.pacbell.net

More articles from Life Sciences:

nachricht Transport of molecular motors into cilia
28.03.2017 | Aarhus University

nachricht Asian dust providing key nutrients for California's giant sequoias
28.03.2017 | University of California - Riverside

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Transport of molecular motors into cilia

28.03.2017 | Life Sciences

A novel hybrid UAV that may change the way people operate drones

28.03.2017 | Information Technology

NASA spacecraft investigate clues in radiation belts

28.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>